Samsung Epis Holdings (0126Z0) stock
KOSPI · Pharmaceuticals
As of the Nov 2 regular-session close (Korea)
- Market cap
- KRW 7.7 trillion
- As of Oct 30, 2026
- P/E
- 90.27x
- Trailing twelve months
- P/B
- 1.26x
- Latest reported equity
- P/S
- 30.60x
- Trailing twelve months
- ROE
- 1.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Oct 30, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Oct 30, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
90.27x
P/B
1.26x
P/S
30.60x
Earnings and dividend metrics▾
Earnings
EPS
KRW 3,429
Earnings per share
BPS
KRW 244,932
Book value per share
ROE
1.4%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 3,429 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 244,932 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 1.4%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 391.9 billion | KRW 58.7 billion | KRW 85.8 billion | — |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 453.9 billion | KRW 90.5 billion | KRW 99.5 billion | — |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed May 15, 2026 | KRW 251.7 billion | -KRW 63.6 billion | KRW 85.3 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 11.95%
- Of trading value on Oct 30, 2026
- Short-sale value
- KRW 1.55 billion
- Previous 20-day average 6.46%
- Net short position
- 41,426 shares
- As of Oct 28, 2026 · reported with a two-trading-day lag
- Lending balance
- 503,779 shares
- As of Oct 30, 2026 · 2.02% of listed shares
| Date | Share | Value |
|---|---|---|
| Oct 30, 2026 | 11.95% | KRW 1.55 billion |
| Oct 29, 2026 | 11.36% | KRW 2.09 billion |
| Oct 28, 2026 | 8.42% | KRW 1.27 billion |
| Oct 27, 2026 | 11.38% | KRW 1.3 billion |
| Oct 26, 2026 | 8.57% | KRW 960 million |
| Oct 23, 2026 | 5.27% | KRW 580 million |
| Oct 22, 2026 | 2.14% | KRW 180 million |
| Oct 21, 2026 | 9.31% | KRW 1.4 billion |
| Oct 20, 2026 | 11.90% | KRW 1.77 billion |
| Oct 19, 2026 | 2.41% | KRW 450 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Report on Changes in Shares Held by the Largest Shareholder and Related PartiesNov 2, 2026 · Largest Shareholder Holding ChangeEnglish
- Technology or Regulatory Approval(Korean)Oct 30, 2026
- Preliminary Consolidated Operating Results (Fair Disclosure)Oct 28, 2026 · Preliminary EarningsEnglish
- Preliminary Consolidated Operating Results (Fair Disclosure; Subsidiary)Oct 28, 2026 · Preliminary EarningsEnglish
- Report on Changes in Shares Held by the Largest Shareholder and Related Parties(Korean)Oct 6, 2026 · Largest Shareholder Holding Change
- Material Management Information(Korean)Oct 1, 2026
- Report on Changes in Shares Held by the Largest Shareholder and Related Parties(Korean)Sep 7, 2026 · Largest Shareholder Holding Change
- Technology or Regulatory Approval(Korean)Aug 10, 2026
Filings with a published English version open in English; the rest link to the Korean original.
Samsung Epis Holdings (0126Z0) stock information
KOSPI
Samsung Epis Holdings (0126Z0) is listed on KOSPI. Its market capitalization is about KRW 7.7 trillion. On trailing-twelve-month earnings the P/E ratio is 90.27, and the P/B ratio is 1.26. Return on equity is 1.4%. These figures are computed in-house from official filings and are reference information only.
Samsung Epis Holdings — frequently asked questions
- What is the P/E ratio of Samsung Epis Holdings (0126Z0)?
- On a trailing-twelve-month basis, 0126Z0 trades at a P/E ratio of 90.27. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Samsung Epis Holdings?
- 0126Z0 has a market capitalization of about KRW 7.7 trillion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.